Savings and the Upsher‑Smith Promise of Support® Program Support that helps you care for your loved one with confidence Managing your child’s Duchenne muscular dystrophy (Duchenne) care can be complex—but getting a prescription treatment shouldn’t be. That’s why the Upsher‑Smith Promise of Support® Program was created—to help families navigate insurance, manage medication delivery, and help make it easier to start and stay on KYMBEE™ (deflazacort) therapy. How our program helps Once your child’s doctor prescribes KYMBEE, the Promise of Support® Program is ready to help. The Upsher‑Smith Promise of Support® Program connects caregivers with Patient Care Coordinators who help guide every step of the access and treatment journey. Confidence through access and coverage navigation Prior authorization and appeal support to help accelerate access and reduce the burden on the family $0 copay* for eligible commercially insured patients Pathways to access therapy, even when insurance challenges arise Helping children start and stay on therapy Quick Start medication supply, available as needed, enables patients to start therapy during the insurance approval process Bridge medication supply provides access to medication while resolving coverage gaps or refill delays Peace of mind for families 24/7 pharmacist access for personalized help, education, and answers every step of the journey Free home delivery of medication Refill reminders and shipment coordination with regular updates so medication supply arrives on time Language translation services available for caregivers and families Getting started with KYMBEE *Limitations apply. When your child is prescribed any medication, it’s natural to have questions along the way. The Upsher‑Smith Promise of Support® Program can help by providing guidance on what to watch for, sharing information about possible side effects, and connecting you with a pharmacist if questions arise. And remember, always tell your child’s doctor about any side effects. Your dedicated Therapy Care Team When your child’s prescription for KYMBEE is received, you’ll be connected with a member of the dedicated Care Team—a group of professionals experienced with deflazacort therapy. Your Care Team will: Contact you and your healthcare provider to confirm prescription details Explain how to take and store your child’s medication Schedule deliveries so they arrive when and where you need them Check in to see how therapy is going and answer your questions Connect you with a pharmacist anytime you need additional support Once enrolled, someone from the Care Team is available 24 hours a day, 7 days a week—so help is always just a call away. Getting started with KYMBEE To learn more about enrolling in our Promise of Support® Program—or to find out how to begin therapy with KYMBEE—talk with your child’s healthcare provider or contact a member of our team. Getting started with KYMBEE Why support matters Not every deflazacort product comes with the same level of support. Because KYMBEE is backed by the Upsher‑Smith Promise of Support® Program, families have access to real people who can help with insurance, savings, delivery, and ongoing questions. With Upsher‑Smith, it’s more than medicine—it’s reliable, coordinated help designed for families caring for children with Duchenne. Ready to get started with KYMBEE and see how our Promise of Support® Program can help? Discover how your Care Team aims to simplify coverage, coordinate delivery, and help your child start—and stay—on deflazacort therapy. Getting started with KYMBEE Explore dosing options Explore FAQs Request to stay informed IMPORTANT SAFETY INFORMATION & INDICATION for KYMBEE™ (deflazacort) Who should not take KYMBEE? Do not take if you have had hypersensitivity, including allergic reactions, to deflazacort (the active ingredient in KYMBEE) or to any of the inactive ingredients in KYMBEE. What is the most important information I should know about KYMBEE? KYMBEE can cause changes in endocrine (hormone) function. Do not stop taking KYMBEE, or change the amount being taken, without first checking with a healthcare provider, as there may be a need for gradual dose reduction to decrease the risk of adrenal insufficiency and steroid “withdrawal syndrome.” Acute adrenal insufficiency can occur if corticosteroids, including KYMBEE, are withdrawn abruptly, and can be life threatening. A steroid “withdrawal syndrome” may also occur following abrupt discontinuance of corticosteroids. For patients already taking corticosteroids during times of stress, the dosage may need to be increased. There is an increased risk of infection when taking KYMBEE. Tell a healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Seek medical advice immediately if the patient develops fever or other signs of infection. Some infections can potentially be severe and life threatening. Patients should avoid exposure to chickenpox or measles and alert their healthcare provider immediately if they are exposed. KYMBEE can cause an increase in blood pressure and water retention. If this occurs, dietary salt restriction and potassium therapy may be needed. There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like KYMBEE. KYMBEE can cause behavior and mood changes that can be severe. Seek medical attention if any behavioral or mood changes develop. There is a risk of osteoporosis with prolonged use of KYMBEE, which can lead to fractures in the spine and in long bones. KYMBEE may cause cataracts or glaucoma. A healthcare provider should monitor for these conditions if therapy is continued for more than 6 weeks. Immunizations should be up-to-date according to immunization guidelines prior to starting therapy with KYMBEE. Live attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting KYMBEE. Live attenuated or live vaccines should not be used in patients taking KYMBEE. KYMBEE can cause serious skin rashes. Seek medical attention at the first sign of a rash. Rare instances of anaphylaxis, a severe allergic reaction, have occurred in patients receiving corticosteroid therapy, including KYMBEE. KYMBEE Oral Suspension contains the preservative benzyl alcohol which can cause serious side effects in infants. It is not approved for use in patients less than 2 years of age. Before taking KYMBEE, tell a healthcare provider about all medical conditions, including if the patient: is pregnant or planning to become pregnant. KYMBEE can harm an unborn baby. is breastfeeding or planning to breastfeed. Deflazacort may appear in breastmilk and could affect a nursing child. Certain medications can cause an interaction with KYMBEE. Tell a healthcare provider about all the medicines you are taking, including over-the-counter medicines (such as insulin, aspirin or other non-steroidal anti-inflammatory drugs), dietary supplements, and herbal products. Alternate treatment, dosage adjustment, and/or special test(s) may be needed during the treatment. What are the side effects of KYMBEE? The most common side effects include: facial puffiness or Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, frequent daytime urination, unwanted hair growth, abdominal obesity, and colds. These are not all of the possible side effects. Call a healthcare provider for medical advice about side effects. What is KYMBEE? KYMBEE (deflazacort) is a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. KYMBEE is available in 6 mg, 18 mg, 30 mg, and 36 mg tablets. KYMBEE is also available as a 22.75 mg/mL oral suspension. This safety information is not comprehensive. Please see the full Prescribing Information for more information on KYMBEE and the Instructions for Use. You can also visit www.upsher-smith.com or call 1-888-650-3789. You are encouraged to report suspected adverse reactions to the FDA by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088.